Palisade Bio (PALI) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary

Company history and strategic pivot

• Originated from UC San Diego science, restructured in summer 2023 after a phase II setback and asset acquisition from Giiant Pharma.

• Acquired a PDE4 inhibitor, reformulated as a prodrug, and advanced it through preclinical and phase I studies.

Scientific and clinical innovation

• PALI-2108 is a once-daily, orally delivered, gut-restricted PDE4 inhibitor designed to minimize systemic side effects.

• Prodrug activation in the distal gut reduces upper GI and CNS adverse events, improving tolerability.

• Demonstrated increased cyclic AMP and modulation of key inflammatory and fibrotic pathways in UC patients.

Clinical development and trial design

• Phase I studies in moderate to severe UC patients showed significant biomarker improvements, 100% response, and 40% remission after one week.

• Upcoming phase II UC trial aims for IND filing in Q2, enrollment in Q3, and top-line data by end of 2027.

• FSCD phase I-B study evaluates safety, tolerability, and pharmacodynamics in a high unmet need Crohn’s population.